Alternative strategies targeting dysregulated cytokine balance could be considered for these patients at high risk of relapse.
-
November 26, 2020 (v1)Journal articleUploaded on: February 22, 2023
-
September 1, 2021 (v1)Book section
Exciting times for the field of renal autoimmune diseases have begun. In 2021, for the first time, two new drugs belimumab (1) and voclosporin ( 2) are approved for the treatment of lupus nephritis (LN) (1, 2). Other novel targeted therapies demonstrate clinical efficacy in large, randomized trials, such as avacopan for ANCA-associated...
Uploaded on: December 4, 2022 -
November 26, 2020 (v1)Journal article
Alternative strategies targeting dysregulated cytokine balance could be considered for these patients at high risk of relapse.
Uploaded on: December 4, 2022 -
December 30, 2019 (v1)Journal article
The phospholipase A2 receptor (PLA2R1) is the major autoantigen in idiopathic membranous nephropathy (MN). However, the pathogenic role of anti-PLA2R1 autoantibodies is unclear. Our aim was to evaluate the in vitro cytotoxicity of anti-PLA2R1 antibodies mediated by complement. Forty-eight patients with PLA2R1-related MN from the prospective...
Uploaded on: December 4, 2022